Troponin I, CK-MB, and inotropic score in hypoxic-ischemic encephalopathy and associated infant mortality.

PURPOSE: Cardiovascular dysfunction is common in hypoxic-ischemic encephalopathy (HIE), which is one of the leading causes of multi-organ failure in neonates. We aimed to assess troponin I and creatine kinase myocardial band (CK-MB) levels, inotropic score (IS) in HIE patients, and their associations with HIE staging and mortality. METHOD: The medical records of all HIE infants admitted to our unit between 2016 and 2018 were retrospectively analyzed. Demographic characteristics of the infants, seizures, anticonvulsive therapies, maximum inotrope doses, and the derived IS (dopamine dose [µg/kg/min] + dobutamine dose [µg/kg/min] + 100 × epinephrine dose [µg/kg/min]) and CK-MB and troponin-I levels obtained in the first six hours of life were compared according to HIE staging. Comparisons between survivors and non-survivors were made. RESULTS: The study included data from 195 patients. Twenty-five patients were classified as stage 3, 116 as stage 2, and 54 as stage 1 HIE. Median Troponin-I, CK-MB level, and IS significantly differed by HIE staging (p < 0.01). The deceased infants had significantly higher median troponin I level [0.36 (0.02-3) vs. 0.16 (0.01-1.1) ng/ml; p = 0.006], median IS [20 (5-120) vs. 5 (5-10); p < 0.001], however, CK-MB values were comparable with survivors [129 (51-300) vs. 60.7 (31-300) ng/ml; p = 0.57]. The area under the curve was 0.93 for IS and 0.81 for Troponin I to predict mortality. CONCLUSION: Troponin I, CK-MB, and IS could be successfully used as disease severity markers in HIE furthermore, troponin I and IS, are good predictors of mortality. These results need to be confirmed with larger prospective multi-center studies.

Taquicardia supraventricular en un recién nacido después del tratamiento con salbutamol nebulizado: A propósito de un caso / Supraventricular tachycardia after nebulized salbutamol therapy in a neonate: Case report

La taquicardia supraventricular (TSV) es el tipo de arritmia sostenida más frecuente en los recién nacidos y lactantes. En general, la presentación de la TSV en los recién nacidos es sutil y, a menudo produce insuficiencia cardíaca congestiva. A pesar del amplio uso de los agonistas p2, su toxicidad ha sido cuestionada. En varios estudios se informó un aumento de la incidencia de arritmias cardíacas en los pacientes que reciben estos agentes, y en otros estudios se hallaron tasas elevadas de muerte cardiovascular asociada con el uso de agonistas p2 nebulizados y orales, como el salbutamol, que se utilizan para tratar el broncoespasmo en los recién nacidos con diversas enfermedades. Informamos un caso de TSV después de la administración de salbutamol nebulizado a un recién nacido.

Supraventricular tachycardia (SVT) is the most common sustained arrhythmia in neonates and infants. Presentation of SVT in the neonate is usually subtle and frequently complicated by congestive heart failure. Despite the widespread use of β2-agonists, their safety has been questioned. Several studies have reported an increased incidence of cardiac arrhythmias in patients treated with these agents, and other studies have found increased rates of cardiovascular death associated with the use of oral and nebulized β2-agonists such as salbutamol, which is used to treat bronchospasm in newborns with several diseases. Herein, we report a case of SVT following administration of nebulized salbutamol in a neonate.

Taquicardia supraventricular en un recién nacido después del tratamiento con salbutamol nebulizado: A propósito de un caso / Supraventricular tachycardia after nebulized salbutamol therapy in a neonate: Case report

La taquicardia supraventricular (TSV) es el tipo de arritmia sostenida más frecuente en los recién nacidos y lactantes. En general, la presentación de la TSV en los recién nacidos es sutil y, a menudo produce insuficiencia cardíaca congestiva. A pesar del amplio uso de los agonistas p2, su toxicidad ha sido cuestionada. En varios estudios se informó un aumento de la incidencia de arritmias cardíacas en los pacientes que reciben estos agentes, y en otros estudios se hallaron tasas elevadas de muerte cardiovascular asociada con el uso de agonistas p2 nebulizados y orales, como el salbutamol, que se utilizan para tratar el broncoespasmo en los recién nacidos con diversas enfermedades. Informamos un caso de TSV después de la administración de salbutamol nebulizado a un recién nacido.(AU)

Supraventricular tachycardia (SVT) is the most common sustained arrhythmia in neonates and infants. Presentation of SVT in the neonate is usually subtle and frequently complicated by congestive heart failure. Despite the widespread use of β2-agonists, their safety has been questioned. Several studies have reported an increased incidence of cardiac arrhythmias in patients treated with these agents, and other studies have found increased rates of cardiovascular death associated with the use of oral and nebulized β2-agonists such as salbutamol, which is used to treat bronchospasm in newborns with several diseases. Herein, we report a case of SVT following administration of nebulized salbutamol in a neonate.(AU)

Supraventricular tachycardia after nebulized salbutamol therapy in a neonate: case report.

Supraventricular tachycardia (SVT) is the most common sustained arrhythmia in neonates and infants. Presentation of SVT in the neonate is usually subtle and frequently complicated by congestive heart failure. Despite the widespread use of ß2-agonists, their safety has been questioned. Several studies have reported an increased incidence of cardiac arrhythmias in patients treated with these agents, and other studies have found increased rates of cardiovascular death associated with the use of oral and nebulized ß2-agonists such as salbutamol, which is used to treat bronchospasm in newborns with several diseases. Herein, we report a case of SVT following administration of nebulized salbutamol in a neonate.